Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Rhea-AI Summary

Rani Therapeutics (Nasdaq: RANI) will present preclinical data on oral semaglutide (RT-116) delivered via the RaniPill® capsule at ObesityWeek® 2025.

The abstract reports that oral semaglutide in dogs was bioequivalent to subcutaneous injections and produced similar weight loss. The poster (No. 647) will be presented by Kyle Horlen, DVM, VP of Nonclinical Development, on November 6, 2025, 2:30–3:30 pm ET at the Georgia World Congress Center, Exhibit Hall A1; the meeting is Nov 4–7, 2025 and includes virtual participation.

News Market Reaction

-12.65%

84 alerts

-12.65% News Effect

+54.0% Peak Tracked

-8.5% Trough Tracked

-$34M Valuation Impact

$234M Market Cap

0.5x Rel. Volume

On the day this news was published, RANI declined 12.65%, reflecting a significant negative market reaction. Argus tracked a peak move of +54.0% during that session. Argus tracked a trough of -8.5% from its starting point during tracking. Our momentum scanner triggered 84 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $34M from the company's valuation, bringing the market cap to $234M at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule, the company’s oral delivery platform, at ObesityWeek® 2025 taking place both virtually and in-person on November 4-7, 2025 in Atlanta, Georgia.

Details of the presentation are as follows:

Abstract Title: Oral Semaglutide (RT-116) in Dogs is Bioequivalent to SC Injections and Elicits Similar Weight Loss
Session Type: Poster Session
Poster Number: 647
Location: Georgia World Congress Center, Exhibit Hall A1
Session Date & Time: November 6, 2025 from 2:30 pm – 3:30 pm E.T.
Presenting Author: Kyle Horlen, DVM, VP of Nonclinical Development

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.

Investor Contact:

investors@ranitherapeutics.com   

Media Contact:

media@ranitherapeutics.com

FAQ

When will Rani Therapeutics present the RT-116 preclinical poster at ObesityWeek 2025 (RANI)?

The poster (No. 647) is scheduled for November 6, 2025, 2:30–3:30 pm ET in Exhibit Hall A1 at the Georgia World Congress Center.

What did Rani report about oral semaglutide (RT-116) in the ObesityWeek 2025 abstract?

The abstract reports that oral RT-116 in dogs was bioequivalent to subcutaneous injections and elicited similar weight loss.

Where can attendees find Rani Therapeutics’ poster at ObesityWeek 2025 (RANI)?

The poster will be located at Georgia World Congress Center, Exhibit Hall A1, Poster No. 647.

Who is presenting Rani Therapeutics’ preclinical data on RT-116 at ObesityWeek 2025 (RANI)?

The presenting author is Kyle Horlen, DVM, VP of Nonclinical Development at Rani Therapeutics.

Will Rani Therapeutics’ ObesityWeek 2025 presentation be available virtually?

ObesityWeek 2025 is taking place both virtually and in person, and the company’s presentation is part of that program.